OSRH CEO Emphasizes Value Enhancement for Biotech Company

In a shareholder letter, CEO Peter Hwang said, in part, "Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries. Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform. Across our portfolio, we are focused on transforming scientific innovation into commercial opportunities and long-term shareholder value. As a holding company, our responsibility is to continually evaluate how best to unlock the value of our underlying businesses for the benefit of shareholders. Public markets have repeatedly demonstrated that significant value can be created through thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions that allow investors to participate more directly in the success of underlying assets. While we are not announcing any specific transaction at this time, I can assure shareholders that we are evaluating a full range of tools available to publicly listed Hub-and-Spoke biotech companies and are committed to pursuing opportunities that we believe will benefit our investors. We continue to work closely with Nasdaq, our advisors, and industry experts regarding our minimum bid price compliance process. Maintaining a Nasdaq listing remains an important objective, and we are evaluating pathways to achieve compliance while preserving and enhancing long-term shareholder value...The next chapter of OSRH will not be defined by a compliance deadline or short-term considerations such as the next quarter or month, but by its ability to translate scientific innovation into enduring shareholder value. We remain confident in our portfolio, our partners, and the opportunities before us, and we appreciate the continued trust and support of our shareholders as we execute our strategy."